Astrocytoma

P=N/A, N=1000, Active, not recruiting, Blokhin's Russian Cancer Research Center

P1, N=110, Active, not recruiting, Universitair Ziekenhuis Brussel | Phase classification: P1/2 --> P1

Using large language model-based data analysis from two NF centers, we compared OPGs in children with NF1, with and without CPP. CPP was associated with hypothalamic involvement, poorer vision, and a higher likelihood of OPG treatment.

P1, N=62, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027

P2, N=37, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026

A literature review showed 12 additional patients diagnosed with Ollier's disease who were subsequently diagnosed with a grade II astrocytoma later in life. After reviewing the genetics behind Ollier's disease, the importance of performing routine cranial magnetic resonance imaging (MRI) in these patients becomes apparent.

Dopamine receptors, particularly DRD2 and DRD3, are emerging as regulators of glioblastoma stem cell maintenance and therapy resistance. Targeting hormone and GPCR-related pathways, especially considering sex-specific factors, offers promising avenues for developing personalized glioblastoma treatments and enhancing current therapy outcomes.

P2, N=70, Not yet recruiting, The Cooper Health System

Patients with hemizygous loss of CDKN2A/B, loss of PTEN, increased number of copy number alterations, specific chromosomal arm losses or rs55705857 germline risk allele have reduced overall survival.

Executive deficits are observed in individuals with brain tumors or survivors, significantly affecting their academic, social, and emotional lives. Early identification, along with educational and neuropsychological support, is essential to preventing these deficits from interfering with academic, personal, and professional functioning.

LITT activated non-classical monocytes, and pembrolizumab unleashed CD8⁺ T cell proliferation, clonal expansion, and coordinated memory T-cell responses. Overall, LITT + PEM is safe and may overcome rHGA immunosuppression to generate antitumor immunity.

P2, N=19, Terminated, Exelixis | Completed --> Terminated; Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.